At the UB School of Pharmacy and Pharmaceutical Sciences, our dynamic research spans drug interaction, from discovery to development to clinical application. We are leading developments in precision pharmacotherapy, resulting in improved patient outcomes and development of future public policy initiatives.

Our world-renowned researchers challenge scientific boundaries and define the future of pharmaceutical research and drug therapy management. Our highly competitive National Institutes of Health (NIH) grant support gives us a powerful foundation that facilitates groundbreaking discoveries and solutions to critical health challenges.

In addition to the Pharmacy Building, the campus boasts an extensive network of clinical and research affiliations, with a variety of local, regional, national and international sites, including Roswell Park Comprehensive Cancer Center, the Nobel Prize-winning Hauptman-Woodward Medical Research Institute, the New York State Center of Excellence in Bioinformatics and Life Sciences, the National Institutes of Health, the ACTG AIDS Clinical Trials Group, and the University of Zimbabwe, Harare.

Research News

  • Drug Discovery, Development and Evaluation Hub Welcomes New Faculty to Fuel Innovation
    The University at Buffalo School of Pharmacy and Pharmaceutical Sciences’ (UB SPPS) Drug Discovery, Development and Evaluation (DDDE) Hub, a leading research engine in the fields of pharmaceutical research and translational sciences, is proud to announce the following strategic news hires who will launch and lead critical components of the DDDE Hub. These renowned faculty hires signify the university’s and the school’s commitment to drug discovery, development and the evaluative sciences as well as its dedication to fostering a culture of innovation and research excellence.
  • Daly and Jacobs receive IPRO Quality Award
    Christopher Daly, PharmD/MBA, and David Jacobs, PharmD, PhD, along with their team, have received a 2024 IPRO Quality Award for their social determinants of health (SDoH) pharmacy program within New York Community Pharmacy Enhanced Services Network (CPESN) member pharmacies.
  • UB’s new mass spectrometer can accelerate discoveries of new drug targets and biomarkers

    State-of-the art equipment arrived at the University at Buffalo Center of Excellence in Bioinformatics and Life Sciences (CBLS) last fall.

  • Abceutics, Inc., a startup at UB, acquired by biopharma company Merck

    Acquisition includes novel platform technology designed to improve the safety and efficacy of an important emerging class of cancer medicines.

  • Sprowl receives $750,000 NSF CAREER Award
    Jason Sprowl, PhD, assistant professor, Department of Pharmaceutical Sciences, is the recipient of a National Science Foundation (NSF) CAREER award, the foundation’s most prestigious honor for early-career faculty. He is the only non-engineering faculty member to receive this in 2024 at UB.

Key Research Strengths

PK/PD, Pharmacometrics and Systems Pharmacology

Collectively, our research in pharmacokinetics and pharmacodynamics (PK/PD), pharmacometrics, and systems pharmacology is having a critical impact on important decision making in drug discovery, development, and clinical utilization and is being used to guide the design of new potential drugs, provide a scientific rationale for new drug combinations, minimize adverse drug reactions, and individualize pharmacotherapy.

Pharmacogenetics, Genomics, Drug Metabolism and Drug Transport

We employ a unique multi-disciplinary approach to these areas of research which study individuals response to particular drugs based on their genomic profile, allowing for the evaluation of genetic variables affecting a person’s response to that particular drug. These approaches combine pharmacology and genomics, providing the key foundational principles of precision medicine.

Protein Therapeutics

We are conducting cutting-edge research that tests hypotheses relating to the pharmacokinetics and pharmacodynamics (PK/PD) of protein drugs, and also relating to the development of new methods for the prediction and characterization of protein PK/PD.

Drug Delivery

Our research is transformative in the development of drug delivery systems for the targeted delivery of therapeutic agents. With a focus on the on the development of protein therapeutic delivery systems as a bio-therapeutic pathways, this research will expand options in the delivery of multiple therapeutic agents and approaches to gene therapy.

Pharmaceutical Health Services and Outcomes Research

We focus on the intersection of pharmaceutical health services and outcomes research, pharmacoepidemiology, comparative effectiveness research and implementation science. Our faculty investigate the impact and outcomes of pharmaceutical products and services while advancing the knowledge about the effectiveness and safety of medicines as well as pharmacy’s role in improving population health. Our approach emphasizes interdisciplinary and collaborative research strategies encompassing both observational and interventional methods across a variety of therapeutic areas.

Clinical and Translational Research

We are accelerating the delivery of basic scientific discoveries from the laboratory to clinical trials, and from clinical trials into general practice.  Our faculty are conducting extensive research in preclinical and early clinical development for novel compounds for investigators.